WuXi Biologics Rises on Vertex Pharma Deal for T-Cell Engager in Autoimmune Disease

WuXi Biologics (2269.HK) shares climbed on February 3, 2026, after announcing a strategic partnership with Vertex Pharmaceuticals (VRTX) to develop a T-cell engager for autoimmune diseases. The collaboration grants Vertex exclusive global rights to the candidate therapy, with WuXi Biologics eligible for up to $1.2 billion in milestone payments plus tiered royalties. Under the agreement, WuXi Biologics will lead early-stage research and preclinical development, while Vertex assumes responsibility for clinical trials and commercialization. The deal marks Vertex’s latest move to expand beyond its core cystic fibrosis franchise into immunology, leveraging WuXi’s proprietary technology platform for novel biologics.